GRAIL is trading 4.1% down at $71.32 as investors remain cautious following the recent NHS-Galleri trial failure and a critical short-seller report.
- The recent trial failure has significantly impacted the stock's valuation, raising major concerns regarding the regulatory and commercial prospects for the Galleri multi-cancer detection test.
- Sentiment is further pressured by a short-seller report alleging operational missteps, weak sales traction, and severe regulatory hurdles.
- Broader weakness in the biotech sector and general market risk-off conditions are contributing to the downward momentum.